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Hitoshi Sakuraba, Alberto Ponzone, and Robert J. Desnick
The classic phenotype of Fabry disease, X-linked a-galactosidase A (a-Gal A) deficiency, has an estimated incidence of
∼1 in 50,000 males. The recent recognition of later-onset variants suggested that this treatable lysosomal disease is more
frequent. To determine the disease incidence, we undertook newborn screening by assaying the a-Gal A activity in blood
spots from 37,104 consecutive Italian male neonates. Enzyme-deficient infants were retested, and “doubly screened-
positive” infants and their relatives were diagnostically confirmed by enzyme and mutation analyses. Twelve (0.03%)
neonates had deficient a-Gal A activities and specific mutations, including four novel missense mutations (M51I, E66G,
A73V, and R118C), three missense mutations (F113L, A143T, and N215S) identified previously in later-onset patients,
and one splicing defect (IVS5+1GrT) reported in a patient with the classic phenotype. Molecular modeling and in vitro
overexpression of the missense mutations demonstrated structures and residual activities, which were rescued/enhanced
by an a-Gal A–specific pharmacologic chaperone, consistent with mutations that cause the later-onset phenotype. Family
studies revealed undiagnosed Fabry disease in affected individuals. In this population, the incidence of a-Gal A deficiency
was 1 in ∼3,100, with an 11:1 ratio of patients with the later-onset:classic phenotypes. If only known disease-causing
mutations were included, the incidence would be 1 in ∼4,600, with a 7:1 ratio of patients with the later-onset:classic
phenotypes. These results suggest that the later-onset phenotype of Fabry disease is underdiagnosed among males with
cardiac, cerebrovascular, and/or renal disease. Recognition of these patients would permit family screening and earlier
therapeutic intervention. However, the higher incidence of the later-onset phenotype in patients raises ethical issues
related to when screening should be performed—in the neonatal period or at early maturity, perhaps in conjunction
with screening for other treatable adult-onset disorders.
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Fabry disease (MIM 301500) is an X-linked lysosomal stor-
age disorder that results from the deficient activity of the
lysosomal glycohydrolase a-galactosidase A (a-Gal A).1
The enzymatic defect leads to progressive accumulation
of globotriaosylceramide (GL-3) and related glycosphin-
golipids, particularly in blood vessels in the skin, kidney,
heart, and brain. Affected males who have little, if any, a-
Gal A activity exhibit the classic phenotype with onset of
angiokeratomas, acroparesthesias, hypohidrosis, and cor-
neal opacities in childhood.1 With advancing age, pro-
gressive lysosomal GL-3 accumulation—particularly in the
vascular endothelium—leads to renal failure, cardiac and
cerebrovascular disease, and premature death.1
During the past 15 years, later-onset cardiac and renal
variants with residual a-Gal A activity due to missense and
splicing mutations have been identified in individuals
who lack the early manifestations of classically affected
patients (i.e., angiokeratoma, acroparesthesias, hypohid-
rosis, and corneal/lenticular abnormalities).2–5 Patients
with the cardiac variant typically present in the 5th–8th
decades of life with left ventricular hypertrophy (LVH),
arrhythmias, and/or cardiomyopathy,3,4,6 whereas patients
with the renal variant who also lack the early classic man-
ifestations develop proteinuria and later-onset end-stage
renal disease (ESRD), typically after age 50 years.5,7–11 More
recently, males and females aged 18–55 years who have
acute cryptogenic strokes were found to have previously
undiagnosed Fabry disease, including ∼30% with classic
manifestations.12
With the availability of effective enzyme-replacement
therapy13–15 and the future prospect of pharmacologic en-
zyme-enhancement therapy,16–19 efforts have been di-
rected to develop screening methods to identify patients
with Fabry disease,20–22 which has an estimated incidence
of 1 in ∼40,000–60,000 males.1,23 Recently, screening of
males in hemodialysis, cardiac, and stroke clinics, by de-
termination of plasma a-Gal A activities, detected previ-
ously undiagnosed Fabry disease in 0.25%–1% of males
undergoing hemodialysis,5,7–11 in ∼3%–4% of males with
LVH or hypertrophic cardiomyopathy,4,6 and in ∼5% of
males with acute cryptogenic strokes12 (table 1). Detection
of patients with unrecognized Fabry disease is important
for family studies, to identify other affected relatives with
this X-linked disease for therapeutic intervention.
32 The American Journal of Human Genetics Volume 79 July 2006 www.ajhg.org
Table 1. Estimated Frequency in Males of Classic and Later-Onset
Phenotypes of Fabry Disease
Phenotype
Frequency
(in Males)
No.
Screened %
Classic:
Estimate1 … ∼.0025
Based on diagnostic data21 … ∼.0017
Later-onset variants:
In patients in cardiac clinics:
LVH4 230 3.0
Hypertrophic cardiomyopathy6 153 3.9
In patients in hemodialysis clinics:
Japan (Kyushu)5 514 1.0
Japan (Tokyo)7 440 .5
United States9 1,903 .5
Austria11 2,046 .24
Italy8 6,378 .25
In patients in stroke clinics (acute cryptogenic strokes)12 432 4.9
Here, we report the screening of 37,104 consecutive
newborn males for Fabry disease by determination of the
a-Gal A activity in dried blood spots. Surprisingly, 12 ne-
onates, or 1 in ∼3,100 males, had deficient a-Gal A activ-
ities and a-Gal A mutations. Molecular modeling studies
and in vitro overexpression of the missense mutations
revealed structural characteristics and residual enzymatic
activities consistent with mutations identified previously
that cause the later-onset phenotype.1,24,25 These findings
provide the first estimate of the incidence of a-Gal A de-
ficiency; emphasize the need to diagnose unrecognized
later-onset Fabry disease in patients in cardiac, renal, and
stroke clinics; and have important implications for mass-
screening programs for newborns that presymptomati-
cally detect this and other treatable later-onset genetic
disorders.
Subjects, Material, and Methods
Newborn Screening
From July 1, 2003, to June 30, 2005, 37,104 consecutive newborn
males from the Piemonte area of northwestern Italy were screened
for a-Gal A deficiency with the use of dried blood spots on filter
paper collected at age 3 d. This population includes individuals
from northern (∼50%) and central-southern (∼40%) Italy, eastern
Europe (∼5%), and Africa (∼5%). The project was approved by
the Piemonte Regional Committee for Newborn Screening,
and parental consent was obtained for Fabry disease testing, as
well as for the other routinely screened diseases. The parents and
available family members of the newborns with a-Gal A defi-
ciency were counseled and were offered testing, medical evalu-
ations, and medical follow-up.
Enzyme Assay, Mutation Analysis, and Microsatellite
Haplotype Studies
Blood-spot a-Gal A activity was determined using a fully auto-
mated technique described elsewhere.20 One unit (U) of enzy-
matic activity was equal to 1 nmol of 4-methylumbelliferyl-a-D-
galactopyranoside cleaved per h. Infants with activities 20% of
the normal mean  SD (7.7  3.1 U/ml whole blood; )np 350
were considered “screen positive,” and a second blood spot was
requested and assayed. Retested newborns with blood-spot a-Gal
A activities1.5 U/ml were recalled with their mothers for plasma
a-Gal A activity determinations.26 Plasma a-Gal A activities of
2.5 U/ml (normal mean  SD p 14.3  3.2 U/ml; )np 150
were considered diagnostic. Genomic DNAs were isolated for a-
Gal A mutation analyses as described elsewhere.27
To determine if the neonates with the same a-Gal A mutations
were related, we performed haplotype analyses with seven mi-
crosatellite markers tightly linked to the a-Gal A gene between
X-chromosome positions 98424692 and 102588188, six of which
(DXS8020, DXS8034, DXS8089, DXS8100, DXS8063, and
DXS8096) were informative, and with 11 SNPs, 2 of which
(rs2071397 and rs1023431) were informative (UCSC Genome
Bioinformatics). Forward primers were fluorescently dye labeled
(Invitrogen Life Technologies). Genomic DNA was amplified in
10-ml volumes with 50 ng of genomic DNA, 2 mM MgCl2, 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 200 nM of each primer, 0.2 mM
dinucleotide triphosphates, and 2 U of Taq DNA polymerase
(AmpliTaq Gold [Applied Biosystems]). The reaction mixtures
were initially incubated at 95C for 10 min and were amplified
for 27 cycles, with denaturation at 94C for 30 s, annealing at
58C for 30 s, extension at 72C for 30 s, and a final extension
step at 72C for 7 min. Microsatellites were analyzed with an ABI
Prism 3100 Genetic Analyzer with the use of GeneScan Analysis
software (v. 3.1.2) and Genotyper software (v. 2.5) (Perkin-Elmer-
Cetus).
Molecular Modeling Studies
Structural modeling of the novel missense mutations was based
on the human a-Gal A crystal structure24 and used the SYBYL/
BIOPOLYMER molecular modeling software (TRIPOS), as de-
scribed for classic and later-onset mutations.25 The structural lo-
cation and the number of atoms influenced by the amino acid
substitution in the main and side chains of the mutant enzyme
were determined.
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Table 2. a-Gal A Activities and Genotypes in 12 Male Neonates Detected by Newborn Screening
Neonate Genotype
a-Gal A Activitya
(U/ml) a-Gal A Mutation
No. of Atoms
Influencedb
Blood
Spot Plasma
Nucleotide
Substitution
Amino Acid
Substitution
Main
Chain
Side
Chain
1 N215S .0 .8 AATrAGT 215 AsnrSer 0 1
2 E66Gc .2 .7 GAGrGGG 66 GlurGly 5 4
3 M51Ic .0 .6 ATGrATA 51 MetrIle 1 0
4 A73Vc .0 .8 GCArGTA 73 AlarVal 5 11
5 N215S .1 .7 AATrAGT 215 AsnrSer 0 1
6 F113L .0 .3 TTTrCTT 113 PherLeu 1 3
7 A143T .1 1.1 GCArACA 143 AlarThr 3 8
8 A143T .2 .6 GCArACA 143 AlarThr 3 8
9 R118Cc .2 .7 CGCrTGC 118 ArgrCys 1 4
10d IVS51GrT .0 .2 AGgtrAGtt Altered 5′ donor consensus sequence … …
11 F113L .0 .2 TTTrCTT 113 PherLeu 1 3
12 A143T .4 .8 GCArACA 143 AlarThr 3 8
a Normal mean (SD) values: 7.7  3.1 U/ml whole blood and 14.3  3.2 U/ml plasma.
b The number of atoms in main and side chains of the a-Gal A structure influenced by a given missense mutation was calculated
through molecular modeling, as described elsewhere.25 The means (SD) (and ranges) for main- and side-chain influences were
14.1  14.9 (0–77) and 17.1  15.7 (0–68), respectively, for 147 classic mutations; 1.7  1.8 (0–6) and 2.9  2.6 (1–8),
respectively, for 15 known later-onset mutations; and 3.0  2.3 (1–5) and 4.8  4.6 (0–11), respectively, for the four novel
mutations.
c Novel missense mutations: E66G resulted from an ArG transition in codon 66, predicting the substitution of a negatively
charged polar Glu by a smaller nonpolar Gly; M51I resulted from a GrA transition in codon 51, predicting the replacement of a
nonpolar Met by a nonpolar Ile; A73V resulted from a CrT transition in codon 73, predicting the substitution of a nonpolar Ala
by a slightly larger nonpolar Val; and R118C resulted from a CrT transition in codon 118, predicting the replacement of a basic
Arg with an uncharged polar, potentially sulfhydryl-binding Cys.
d IVS51GrT p Intervening sequence of intron 5, grt transition of the consensus “gt” to “tt”of the 5′ donor splice site.
In Vitro Overexpression Studies
In vitro overexpression and characterization of the missense mu-
tations were performed as described elsewhere, except that the
eukaryotic expression vector used was pcDNA 3.0 (Invitrogen Life
Technologies).28 Mutant constructs were generated using the
GeneTailor site-directed mutagenesis kit (Invitrogen Life Tech-
nologies). Transient transfections of COS-7 cells with each a-Gal
A cDNA construct (∼1 mg DNA) and determination of the ex-
pressed intracellular a-Gal A activities were performed as de-
scribed elsewhere.28 COS-7 cells were incubated in the presence
or absence of 20 mM deoxygalactonojirmycin (DGJ), and the in-
tracellular a-Gal A activities were measured 72 h after transfec-
tion.16 Results are expressed as the mean (SD) of at least three
independent transfections for each construct.
Results
Screening of Newborn Males
Initial screening of a-Gal A activity in blood spots from
37,104 consecutive newborn males detected 41 (0.11%)
neonates with enzyme levels 20% of the mean normal
activity. The physicians and families of all 41 neonates
were contacted, and a second blood spot was obtained
from each neonate, as well as one from each mother.
When retested, 12 (0.03%) neonates had a-Gal A activities
20% of the normal mean, whereas the other 29 had
higher enzyme activities ranging from 2.5 to 6.1 U/ml
whole blood. Table 2 shows the enzyme activities in the
blood spots and plasma from the 12 “doubly screened-
positive” neonates whose a-Gal A activities ranged from
0.0 to 0.4 U/ml whole blood and from 0.2 to 1.1 U/ml
plasma. Plasma a-Gal A activities of the 12 mothers ranged
from 14.7% to 43.4% of the mean normal value.
Mutation Analysis and Haplotype Studies
Sequencing of the a-Gal A gene in genomic DNAs from
the 12 enzyme-deficient neonates identified four novel
mutations (M51I, E66G, A73V, and R118C) and four
known mutations reported elsewhere (F113L, A143T,
N215S, and IVS51GrT)27,29,30 (table 2). The respective mu-
tation was present in each neonate’s mother. The four
novel mutations were not detected in 1400 X chromo-
somes from normal individuals, which indicated that they
were not common sequence variants or polymorphisms.
Analyses of informative, closely linked microsatellite
markers surrounding the a-Gal A gene revealed that the
two neonates with the N215S and the three neonates with
the A143T genotypes were not related (three markers dif-
fered in the two neonates’ N215S alleles, and one marker
differed in each of the three neonates’ A143T alleles). In
contrast, the relatedness of the two neonates with the
F113L alleles could not be excluded (no markers differed).
On the basis of the deficient a-Gal A activities and detec-
tion of specific a-Gal A mutations, the diagnosis of Fabry
disease was predicted in these 12 neonates, for an inci-
dence of 1 in ∼3,100 males in this population. If the four
novel missense mutations were excluded, the incidence
Figure 1. Structural changes and molecular modeling of a-Gal A mutations. A, Locations in the a-Gal A crystal structure of the seven
missense mutations identified in neonates by newborn screening. B and C, Molecular modeling studies comparing the number of main-
chain and side-chain atoms influenced by various amino acid substitutions in a-Gal A missense mutations that cause different phe-
notypes.25 These include known mutations causing the classic phenotype (black circles), known later-onset mutations (F113L, A143T,
and N215S) identified in the neonates (red squares), novel mutations (M51I, E66G, A73V, and R118C) identified in the neonates (green
triangles), and other known later-onset mutations (yellow squares). Panel C is an enlargement of the boxed area in panel B that contains
the known later-onset mutations and the novel mutations identified in the neonates. See table 2 for main- and side-chain values.
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Table 3. In Vitro Overexpression of a-Gal A Missense
Mutations in COS-7 Cells
Mutation
% of Expressed
a-Gal A
Wild-Type
Activitya
(No
Treatment)
Fold Increase
over Untreated
Expressed
Wild-Type
Activityb
(20 mM DGJ)
Wild type 100 1.05
Classic mutations:
C172G !1 ND
D264Y !1 ND
Known later-onset mutations:
F113L 38 1.50
A143T 36 1.61
N215S 47 1.79
Novel mutations:
M51I 36 2.25
E66G 39 1.95
A73V 44 1.77
R118C 29 1.10
Pseudodeficiency allele:
D313Y28,34 67 ND
NOTE.—Transiently transfected COS-7 cells were cultured in the pres-
ence or absence of 20 mM DGJ for 72 h, and then the intracellular a-
Gal A activity was assayed. The activities are expressed as the percentage
of the untreated mean expressed wild-type activity. All results are the
means of at least three independent transfections.
a Mean activity of expressed wild-type human a-Gal A was 16.5 mmol/
h/mg protein.
b ND p not determined.
of known disease-causing mutations would be 1 in ∼4,600
males.
Molecular modeling studies of the novel missense mu-
tations (fig. 1A) indicated that the substituted residues
could be accommodated in the a-Gal A crystal structure
and that the numbers of “influenced” main- and side-
chain atoms were similar to those of known later-onset–
causing mutations (fig. 1B and 1C and table 2).
In Vitro Overexpression of Novel Missense Mutations
In vitro transient overexpression in COS-7 cells with each
of the seven missense mutations revealed that they all had
in vitro residual activities between 29% and 47% of the
mean (SD) transiently expressed wild-type activity (16.5
 1.5 mmol/h/mg protein; range 14.3–18.7 mmol/h/mg
protein) (table 3). The high levels of expression were con-
sistent with the simultaneous translation and transcrip-
tion of multiple copies of the mutant constructs,
whereas these mutant alleles had low levels of activity
(!5% of normal) in the plasma or tissues of patients with
the later-onset phenotype.28,31–33 In contrast, transiently
overexpressed missense mutations from patients with the
classic phenotype (e.g., C172G and D246Y) had activities
that were 1% of the mean expressed wild-type activity.
Also, the only known pseudodeficiency allele, D313Y, had
∼60%–67% of the mean expressed wild-type activity and
no clinical phenotype.28,34 Incubation of the pharmaco-
logic chaperone, DGJ, in the media of the COS-7 cells
enhanced the transiently expressed activities of the three
known later-onset mutations and three of the novel mis-
sense mutations 1.50- to 2.25-fold (table 3), as demon-
strated elsewhere for rescuable a-Gal A mutations with
residual a-Gal A activities.16,19
Pedigree Studies
In each of the 12 families, genetic counseling was provided
to the parents, and, after pedigree analysis, diagnostic test-
ing was offered to at-risk family members (fig. 2). All 12
mothers, aged 23–38 years, were heterozygous for the re-
spective a-Gal A mutations. The 34- and 32-year-old
mothers of newborns 1 (N215S) and 10 (IVS51GrT), re-
spectively, had mild proteinuria (75 and 150 mg/day, re-
spectively); neither had cardiac involvement. Newborns
2, 3, 6, and 10 each had one sibling; only the sister of
newborn 10 (IVS51GrT) inherited the family mutation.
Information on the maternal grandparents was limited
because of their availability, interest, or demise. Three ma-
ternal grandfathers (families 3, 8, and 10) had the family
mutation but had not received a previous diagnosis. The
63-year-old grandfather of newborn 3 (M51I) had mild
hypertrophic cardiomyopathy. The 58-year-old grandfa-
ther of newborn 8 (A143T) went into renal failure of un-
known etiology at age 52 years and had a stroke at age 54
years. The grandfather of newborn 10 (IVS51GrT) had hy-
pertrophic cardiomyopathy and died at age 60; his 58-
and 62-year-old sisters had cardiac disease and stroke,
respectively.
Six maternal grandmothers (families 1, 2, 4, 6, 11, and
12) were heterozygous—five confirmed by mutation anal-
ysis and one by pedigree analysis (fig. 2). The 62-year-old
grandmother of newborn 6 (F113L) had cardiomyopathy,
a complete atrial ventricular (AV) block, and a pacemaker;
her 60-year-old brother had hypertrophic cardiomyopa-
thy and previously unrecognized Fabry disease. The de-
ceased great-grandmother of newborn 7 (A143T) had three
brothers who died from cardiac disease. In family 11
(F113L), the 57-year-old heterozygous grandmother had
LVH, and her 34-year-old affected son had hypertrophic
cardiomyopathy and previously unrecognized Fabry dis-
ease. In the remaining three families (5, 7, and 9), addi-
tional medical information was unavailable.
Discussion
During the past decade, the clinical spectrum of Fabry
disease expanded from the classic phenotype, first de-
scribed independently in 1898 by Fabry in Germany35 and
by Anderson in England,36 to include the later-onset sub-
types, which were designated the “cardiac” and “renal”
variants.1–5 Cardiac variants were first recognized in the
early 1990s,2–4 and renal variants were recently identified
by the screening of male patients undergoing chronic
hemodialysis.5,7–11 Most recently, later-onset cerebrovas-
cular variants were detected among patients with pre-
Figure 2. Family pedigrees of the 12 neonates with a-Gal A deficiency detected by newborn screening. Arrow indicates neonate
proband. Males with Fabry disease (solid black squares) were identified by deficient a-Gal A enzyme activities, and heterozygous females
(half black circles) were identified by a-Gal A mutation analysis. Mutations are listed below and ages are listed above the symbols.
Clinical manifestations include hypertrophic cardiomegaly (HCM), LVH, complete AV block, transient ischemic attack (TIA), and ESRD.
NL-Enz p males with normal a-Gal A enzyme activity; NL-DNA p males or females with no a-Gal A mutation; symbols with number
and question mark p number of male or female relatives unavailable for evaluation; and diamonds p sex unknown.
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mature acute cryptogenic strokes.12 Affected males with
the classic subtype have little, if any, a-Gal A activity,
whereas the males with the later-onset cardiac and renal
subtypes have missense or splicing mutations encoding
residual a-Gal A activity, which is responsible for their lack
of the early classic manifestations and for their difficult
diagnoses. The specific mutations of the cerebrovascular
variants were not reported, but at least 30% had the classic
phenotype.12 Although the prevalences of the cardiac, re-
nal, and cerebrovascular variants have been estimated
from pilot studies in cardiac, hemodialysis, and stroke
clinics4–6,8,11,12 (table 1), the combined prevalence of the
later-onset subtypes has not been studied.
Our screenings of 137,000 consecutive newborn males
in northwestern Italy found the surprisingly high inci-
dence of a-Gal A deficiency of ∼1 in 3,100 males in this
population, or ∼15–20 times higher than previously
estimated.1,37 In the 12 a-Gal A–deficient newborns, the
enzymatic diagnosis was confirmed by detection of a spe-
cific a-Gal A mutation in each neonate and his hetero-
zygous mother. Eight newborns had four known a-Gal A
mutations, including a splice-site mutation (IVS51GrT)
that occurred in a patient with the classic phenotype30
and three missense mutations (F113L, A143T, and N215S)
identified in patients with residual a-Gal A activities and
later-onset phenotypes.8,10,27,29 The A143T mutation was
the most common lesion detected in males screened in
hemodialysis clinics.8–10
Four newborns had novel missense mutations (E66G,
M51I, A73V, and R118C) that had structural characteris-
tics and in vitro overexpression levels similar to those of
known later-onset missense mutations. Molecular mod-
eling indicated that the four novel mutant enzymes did
not alter the active site, could be accommodated in the
crystal structure, and affected similar numbers of atoms
in their main and side chains as known later-onset mu-
tations did25 (fig. 1 and table 2). These studies predicted
that the mutant proteins encoded by the novel missense
mutations would not interfere with catalysis but presum-
ably had altered stabilities, making them excellent can-
didates for rescue by pharmacologic chaperones,16,18,19 as
shown when they were incubated with the a-Gal A–spe-
cific pharmacologic chaperone, DGJ (table 3). It should be
noted that the in vitro overexpression of the multiple mu-
tant constructs transfected simultaneously into COS-7
cells can be compared only with that of other overex-
pressed mutations and not with the in vivo activities in
affected males or heterozygotes who have only one mu-
tant gene in their cells. Thus, these studies indicated that
the novel missense mutations encoded enzyme proteins
with rescuable residual activities, consistent with their pre-
diction of the later-onset phenotype.
Of the 12 neonates with a-Gal A deficiency, only one
had a known mutation causing the classic phenotype, for
an incidence of ∼1 in 37,000 males, consistent with pre-
vious estimates for the classic phenotype.1,23 In contrast,
11 neonates had mutations predicting the later-onset phe-
notype, for an 11:1 ratio of later-onset:classic phenotypes.
Although it is not known if all the individuals with novel
mutations will develop disease manifestations, it is no-
table that the affected 60-year-old grandfather of newborn
3 (M51I) had hypertrophic cardiomyopathy. Even if the
novel mutations are excluded, the incidence of a-Gal A
deficiency was 1 in ∼4,600 males, with a 7:1 ratio of later-
onset:classic phenotypes. Clearly, studies in other popu-
lations are required to confirm the high incidence of the
later-onset phenotypes, since disease frequency variations
may occur in different ethnic or demographic groups.
Also, the finding of the same later-onset mutations (i.e.,
N215S and A143T) in newborns with different haplotypes
indicates the absence of a founder effect for these lesions
and reduces the likelihood that the high incidence of later-
onset Fabry disease is an isolated occurrence. Whatever
the incidence of a-Gal A deficiency and symptomatic Fa-
bry disease in different populations, the high incidence
found by newborn screening and the continued screen-
ing/identification of the later-onset phenotype in patients
in cardiac, hemodialysis, and stroke clinics emphasize the
fact that the later-onset phenotype of this panethnic dis-
ease is more prevalent than was previously appreciated.
General physicians and cardiologists should consider
the diagnosis of Fabry disease in patients with LVH, car-
diomyopathy, and conduction abnormalities, including
short PR intervals and inverted ST segments without evi-
dence of an infarction. The presence of microalbuminuria,
or frank proteinuria, isosthenuria, and/or decreasing renal
function should alert nephrologists to consider Fabry dis-
ease in the differential diagnosis. As demonstrated by the
family studies of the 12 affected newborns identified here,
relatives with cardiac or renal disease who had not re-
ceived a Fabry diagnosis were affected or heterozygous for
this X-linked disease. The determination of the a-Gal A
activity in plasma or in isolated leukocytes can reliably
identify affected males with all subtypes,1 and subsequent
genotyping can provide genotype/phenotype correlations
and accurate identification of heterozygous females.1 In
addition, the availability of safe and effective enzyme re-
placement therapy13–15 and the future prospect for phar-
macologic chaperone therapy16,18,19 emphasize the impor-
tance of diagnosing later-onset Fabry disease for early
therapeutic intervention.
Genetic screening has proven effective for the identi-
fication of neonates with inherited metabolic diseases who
require early therapeutic intervention37,38 and for the pre-
natal or perinatal detection of carriers of genetic disorders
in high-risk populations, such as cystic fibrosis in whites,39
Tay-Sachs disease in Ashkenazi Jews,40 and various hemo-
globinopathies in targeted racial, ethnic, and demo-
graphic populations.41 Newborn screening has proven so
effective in identifying and treating infants with inherited
metabolic disorders that efforts are under way to expand
the disease menu by employing tandem mass spectros-
copy, which can detect 140 disorders.42,43 Efforts also are
under way to develop high-throughput newborn screen-
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ing for lysosomal storage diseases.20–22 In our study, new-
born screening revealed the surprisingly high incidence
of later-onset Fabry disease of ∼1:3,100 to ∼4,600 (with
and without the novel mutations), compared with ∼1:
37,000 for the classic phenotype. The higher incidence of
the later-onset phenotype raises the question of when ge-
netic screening for this disease should be undertaken—in
the neonatal period or at early maturity (e.g., age 18–21
years), with informed consent and genetic counseling and
perhaps in conjunction with screening for other treatable
later-onset disorders. Clearly, early detection, genetic
counseling, and therapeutic intervention for the classic
phenotype is beneficial,13–15,44 but the issue of when to
screen for the later-onset variants of Fabry and other treat-
able diseases that also present in childhood raises ethical
issues for consideration and debate.
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